Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E<sub>2</sub> release
Article 2004 en
Authors
JC
Joanna E. Chivers
LC
Lisa Cambridge
MC
Matthew C. Catley
Abstract
1 min read
In A549 pulmonary cells, the dexamethasone‐ and budesonide‐dependent repression of interleukin‐1β‐induced prostaglandin E 2 release was mimicked by the steroid antagonist, RU486. Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleukin‐1β‐induced cyclooxygenase (COX)/prostaglandin E synthase (PGES) activity and COX‐2 expression, RU486 (< 1 µ m ) was a poor inhibitor, but was able to efficiently antagonize the effects of dexamethasone and budesonide. In addition, both dexamethasone and RU486 repressed [ 3 H]arachidonate release, which is consistent with an effect at the level of phospholipase A 2 activity. By contrast, glucocorticoid response element‐dependent transcription was unaffected by RU486 but induced by dexamethasone and budesonide, whilst dexamethasone‐ and budesonide‐dependent repression of nuclear factor‐κB‐dependent transcription was maximally 30–40% and RU486 (< 1 µ m ) was without significant effect. Thus, two pharmacologically distinct mechanisms of glucocorticoid‐dependent repression of prostaglandin E 2 release are revealed. First, glucocorticoid‐dependent repression of arachidonic acid is mimicked by RU486 and, second, repression of COX/PGES is antagonized by RU486. Finally, whilst all compounds induced glucocorticoid receptor translocation, no role for glucocorticoid response element‐dependent transcription is supported in these inhibitory processes and only a limited role for glucocorticoid‐dependent inhibition of nuclear factor‐κB in the repression of COX‐2 is indicated.
Matthew C. Catley, Joanna E. Chivers, Lisa Cambridge, Neil S. Holden, Donna M. Slater, Karl J. Staples, Martin Bergmann, Peter Löser, Peter J Barnes, Robert Newton
Discussion(0)
No comments yet. Be the first to comment.